Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib to Reverse Gastric Intestinal Metaplasia After Early Gastric Cancer/Adenoma Treatment
jRCTs031200052Completed
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of trametinib in Intestinal metaplasia, atrophic gastritis (AG), gastric cancer (GC) and 1 more, sponsored by Nobelpharma Co., Ltd. Started Nov 2022; status: completed.
02
Drugs
trametinib
03
Conditions
Intestinal metaplasiaatrophic gastritis (AG)gastric cancer (GC)gastric adenoma
Beyond the preview
Go deeper on jRCTs031200052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200052.